Examkin

Soru

Zorluk: ZorHematology and Oncology

A 6262-year-old man is hospitalized for the treatment of an acute right-sided pulmonary embolism. He is initially started on a continuous intravenous unfractionated heparin infusion. On hospital day 6, his platelet count is noted to have decreased from a baseline of 240,000/mm3240,000/mm^3 on admission to 90,000/mm390,000/mm^3. Concurrently, he reports new-onset left leg pain and swelling. Venous duplex ultrasonography reveals a new acute deep venous thrombosis in the left femoral vein. Heparin-induced thrombocytopenia is suspected. The heparin infusion is immediately discontinued, and intravenous argatroban is initiated. A serotonin release assay later returns positive, confirming the diagnosis. Four days later, the patient's leg swelling has significantly improved, and his respiratory status remains stable. His current platelet count is 115,000/mm3115,000/mm^3. The patient is eager to transition to an oral anticoagulant and be discharged. Which of the following is the most appropriate next step in the management of this patient's anticoagulation?

  1. A
    Initiate warfarin therapy immediately and continue argatroban until the INR is therapeutic
  2. Delay the initiation of warfarin until the platelet count recovers to at least 150,000/mm3150,000/mm^3Cevap
  3. C
    Discontinue argatroban and initiate subcutaneous enoxaparin as a bridge to warfarin
  4. D
    Administer a pooled platelet transfusion to correct the thrombocytopenia, then initiate warfarin
  5. E
    Discontinue argatroban and initiate a prophylactic dose of subcutaneous fondaparinux

Cevap

Delay the initiation of warfarin until the platelet count recovers to at least 150,000/mm³.
The correct approach is to delay the initiation of warfarin until the patient's platelet count has recovered to at least 150,000/mm3150,000/mm^3. Heparin-induced thrombocytopenia (HIT) is a highly prothrombotic state caused by IgG autoantibodies against platelet factor 4 (PF4) complexed with heparin. These antibodies activate platelets, leading to consumptive thrombocytopenia and paradoxical thrombosis. When transitioning a patient with HIT to long-term oral anticoagulation with warfarin, timing is critical. Warfarin exerts its effect by inhibiting the vitamin K-dependent synthesis of procoagulant factors (II, VII, IX, and X) as well as the endogenous anticoagulant proteins C and S. Because protein C has a significantly shorter half-life (approximately 8 hours) than most procoagulant factors (e.g., factor II has a half-life of 60 hours), the initiation of warfarin creates a transient hypercoagulable window. If warfarin is started during the acute phase of HIT (while platelets are still low and the thrombotic drive is highest), this rapid depletion of protein C can lead to catastrophic microvascular thrombosis, classically presenting as venous limb gangrene or warfarin-induced skin necrosis. Therefore, a non-heparin parenteral anticoagulant (such as argatroban) must be continued alone until the acute phase has resolved, indicated by a platelet count recovery to ≥150,000/mm3\geq 150,000/mm^3. At that point, warfarin can be initiated with a minimum 5-day overlap with the parenteral agent until the INR is therapeutic.

Adım Adım Çözüm

1
Identify the patient's current clinical status.
The patient has confirmed heparin-induced thrombocytopenia (HIT) complicated by a new deep venous thrombosis, currently treated with argatroban. His platelet count is recovering but is still low at 115,000/mm3115,000/mm^3.
Establishing the current phase of HIT (acute vs. recovering) is necessary to guide the transition to long-term oral anticoagulation.
2
Determine the safety of initiating warfarin in the acute phase of HIT.
Warfarin cannot be safely initiated while the patient is still thrombocytopenic (platelets < 150,000/mm3150,000/mm^3).
Warfarin causes rapid depletion of the anticoagulant protein C before it depletes procoagulant factors. In the already highly prothrombotic state of HIT, this can precipitate venous limb gangrene.
3
Select the appropriate next step in management.
The initiation of warfarin must be delayed until the platelet count reaches at least 150,000/mm3150,000/mm^3.
Waiting for platelet recovery ensures the acute prothrombotic phase of HIT has resolved sufficiently to safely tolerate the transient protein C depletion caused by warfarin.

Anahtar Kavram

In patients with heparin-induced thrombocytopenia, warfarin initiation must be delayed until the platelet count recovers to at least 150,000/mm³ to prevent venous limb gangrene.
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru